Despite the possibility of impending changes to current healthcare regulations, it appears, at least for the moment, that value-based purchasing and bundled payment plans are here to stay. As a result, hospitals and health systems must scrutinize their decision-making processes around health technology acquisitions, product standardization, and utilization management. As part of that process, it is incumbent upon both supply chain/value analysis professionals and clinicians to consider three important questions:
- Does the technology work?
- Is the technology safe?
- For which patient population does it work?
“High-quality evidence can guide supply chain professionals, working in concert with their physicians, to select the best products for care delivery while establishing a standard of care.”
In addition to safety, efficacy, and patient populations, value analysis teams in particular must account for the cost-effectiveness of a technology. This is especially true when there is another health technology on the market with the claims of meeting the above criteria, but that comes in at a price point that is markedly higher or lower than its competitors. But how do you determine that information?
Much has been said recently of the role of evidence in healthcare. A recent essay published in ProPublica noted the significant and potentially drastic consequences of the lack of quality evidence integrated into the delivery of care. Similarly, high-quality evidence can guide supply chain professionals, working in concert with their physicians, to select the best products for care delivery while establishing a standard of care.
“But it takes time, resources, and expertise to compile, let alone analyze the full body of existing published, peer-reviewed evidence. Who has the answer? We do.”
But it takes time, resources, and expertise to compile, let alone analyze the full body of existing published, peer-reviewed evidence. There are budgets to be met, patients who require care, and electronic health records (EHR) to manage. Not to mention that not all supply chain professionals have a clinical background, which presents an additional challenge in interpreting the literature. Who has the answer?
Register for “Making the Grade: Utilizing Evidence for Health Technology Decisions.” In our FREE webinar, we’ll address:
- The link between health technology assessments (HTAs) and evidence-based decision-making
- The Hayes methodology for conducting HTAs and determining the Hayes Rating
- How to apply the Hayes Rating to health technology acquisition and utilization processes
In addition, selected participants will receive FREE access to a full report, “Comparative Effectiveness of Bupivacaine Liposome Injectable Suspension for Relief of Postoperative Pain Following Joint Arthroplasties” which will be used as a case study for the webinar.
Don’t miss this chance to get an in-depth look at a comparative effectiveness review (CER), an invaluable tool for health systems participating in bundled payment plans. The webinar take place on Thursday, March 30th. Register below today!